PRAC recommendations on signals
Adopted at the 7-10 June 2021 PRAC meeting

This document provides an overview of the recommendations adopted by the Pharmacovigilance Risk Assessment Committee (PRAC) on the signals discussed during the meeting of 7-10 June 2021 (including the signal European Pharmacovigilance Issues Tracking Tool [EPITT] reference numbers).

PRAC recommendations to provide supplementary information are directly actionable by the concerned marketing authorisation holders (MAHs). PRAC recommendations for regulatory action (e.g. amendment of the product information) are submitted to the Committee for Medicinal Products for Human Use (CHMP) for endorsement when the signal concerns Centrally Authorised Products (CAPs), and to the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for information in the case of Nationally Authorised Products (NAPs). Thereafter, MAHs are expected to take action according to the PRAC recommendations.

When appropriate, the PRAC may also recommend the conduct of additional analyses by the Agency or Member States.

MAHs are reminded that in line with Article 16(3) of Regulation No (EU) 726/2004 and Article 23(3) of Directive 2001/83/EC, they shall ensure that their product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations published on the European Medicines Agency (EMA) website (currently acting as the EU medicines webportal).

For CAPs, at the time of publication, PRAC recommendations for update of product information have been agreed by the CHMP at their plenary meeting (21-24 June 2021) and corresponding variations will be assessed by the CHMP.

For nationally authorised medicinal products, it is the responsibility of the National Competent Authorities (NCAs) of the Member States to oversee that PRAC recommendations on signals are adhered to.

Variations for CAPs are handled according to established EMA procedures. MAHs are referred to the available guidance. Variations for NAPs (including via mutual recognition and decentralised procedures) are handled at national level in accordance with the provisions of the Member States.

---

1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals.
2 The relevant EPITT reference number should be used in any communication related to a signal.
The timeline recommended by PRAC for submission of variations following signal assessment is applicable to both innovator and generic medicinal products, unless otherwise specified.

For procedural aspects related to the handling of PRAC recommendations on signals (e.g. submission requirements, contact points, etc.) please refer to the Questions and Answers on signal management.
1. Recommendations for update of the product information

1.1. Ceftriaxone – Hepatitis

<table>
<thead>
<tr>
<th>Authorisation procedure</th>
<th>Non-centralised</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPITT No</td>
<td>19603</td>
</tr>
<tr>
<td>PRAC rapporteur(s)</td>
<td>Zane Neikena (LV)</td>
</tr>
<tr>
<td>Date of adoption</td>
<td>10 June 2021</td>
</tr>
</tbody>
</table>

**Recommendation**

Considering the available evidence (e.g. EudraVigilance, literature), as well as a plausible biological mechanism of action, the strength of the causal relationship of hepatotoxicity with the use of ceftriaxone is sufficient to update the product information. Therefore, all MAHs for ceftriaxone containing medicinal products should submit a variation within 2 months to amend the product information as described below (new text in bold and underlined; remove strikethrough text):

**Summary of product characteristics**

4.8. Undesirable effects

Under SOC Hepatobiliary disorders with frequency "Not known"

**Hepatitis**

**Hepatitis cholestatic**

b See section 4.4

c Usually reversible upon discontinuation of ceftriaxone

**Package leaflet**

4. Possible side effects

Under frequency "Not known"

Problems with gallbladder and/or liver, which may cause pain, nausea, vomiting, feeling sick, and being sick, yellowing of the skin, itching, unusually dark urine and clay-coloured stools.

---

3 Translations in all official EU languages of the new product information adopted by PRAC are also available to MAHs on the EMA website.
1.2. Tofacitinib – Major adverse cardiovascular events (MACE) and malignancies excluding non-melanoma skin cancer (NMSC) from a clinical trial

<table>
<thead>
<tr>
<th>Authorisation procedure</th>
<th>Centralised</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPITT No</td>
<td>19382</td>
</tr>
<tr>
<td>PRAC rapporteur(s)</td>
<td>Liana Gross-Martirosyan (NL)</td>
</tr>
<tr>
<td>Date of adoption</td>
<td>10 June 2021</td>
</tr>
</tbody>
</table>

Recommendation [see also section 3]

Having considered the data from the completed post-authorisation safety study A3921133 and responses submitted by the MAH, the PRAC has agreed that the Marketing Authorisation Holder (MAH) for Xeljanz (Pfizer) should submit a variation within 2 months from the publication of the PRAC recommendation, to amend the product information as described below (new text underlined, text to be removed struck-through):

Summary of product characteristics

4.2. Posology and method of administration

Elderly
No dose adjustment is required in patients aged 65 years and older. There are limited data in patients aged 75 years and older. See section 4.4 for Use in patients over 65 years of age.

4.4. Special warnings and precautions for use

Use in patients over 65 years of age

Considering the increased risk of serious infections, myocardial infarction, and malignancies with tofacitinib in patients over 65 years of age, tofacitinib should only be used in these patients if no suitable treatment alternatives are available (see further details below in section 4.4 and section 5.1).

The risks and benefits of treatment should be considered prior to initiating tofacitinib in patients:

- who are over 65 years of age

As there is a higher incidence of infections in the elderly and in the diabetic populations in general, caution should be used when treating the elderly and patients with diabetes (see section 4.8). In patients over 65 years of age tofacitinib should only be considered used if no suitable alternative treatment alternatives are available (see section 5.1).

Viral reactivation

[...]

Major adverse cardiovascular events (including myocardial infarction)

Major adverse cardiovascular events (MACE) have been observed in patients taking tofacitinib.

In a randomised post authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, an increased incidence of myocardial infarctions was observed with tofacitinib compared to TNF inhibitors (see sections 4.8 and 5.1). In patients over 65 years of age, patients who are current or past smokers, and patients with other cardiovascular risk factors, tofacitinib should only be used if no suitable treatment alternatives are available.
Malignancy and lymphoproliferative disorder

The risks and benefits of tofacitinib treatment should be considered prior to initiating therapy in patients with current or a history of malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing tofacitinib in patients who develop a malignancy. The possibility exists for tofacitinib to affect host defences against malignancies.

Lymphomas have been observed in patients treated with tofacitinib. Patients with RA, particularly those with highly active disease may be at a higher risk (up to several-fold) than the general population for the development of lymphoma. The effect of tofacitinib on the development of lymphoma is uncertain.

Other malignancies were observed in clinical studies and the post-marketing setting, including, but not limited to, lung cancer, breast cancer, melanoma, prostate cancer, and pancreatic cancer.

The effect of tofacitinib on the development and course of malignancies is not known.

Tofacitinib may affect host defences against malignancies.

In a randomised post-authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, an increased incidence of malignancies excluding NMSC, particularly lung cancer and lymphoma, was observed with tofacitinib compared to TNF inhibitors (see sections 4.8 and 5.1).

Lung cancers and lymphoma in patients treated with tofacitinib have also been observed in other clinical studies and in the post marketing setting.

Other malignancies in patients treated with tofacitinib were observed in clinical studies and the post-marketing setting, including, but not limited to, breast cancer, melanoma, prostate cancer, and pancreatic cancer.

In patients over 65 years of age, patients who are current or past smokers, and patients with other malignancy risk factors (e.g. current malignancy or history of malignancy other than a successfully treated non-melanoma skin cancer) tofacitinib should only be used if no suitable treatment alternatives are available.

**Cardiovascular risk**

RA and PsA patients have an increased risk for cardiovascular disorders. Patients treated with tofacitinib should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care.

4.8. Undesirable effects

The most commonly reported adverse reactions during the first 3 months of the double-blind, placebo or MTX controlled clinical trials were headache, upper respiratory tract infections, nasopharyngitis, diarrhoea, nausea and hypertension (see Table 6, Adverse Drug Reactions [ADRs] based on all study durations).

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Frequency uncommon: Lung cancer
Frequency rare: Lymphoma

SOC: Cardiac disorders
Frequency uncommon: Myocardial infarction

**Rheumatoid arthritis**

In a large, randomised post-authorisation safety surveillance study of rheumatoid arthritis patients who were 50 years of age and older and had at least one additional cardiovascular (CV) risk factor, VTE was observed at an increased and dose-dependent incidence in patients treated with tofacitinib compared to TNF inhibitors. The majority of these events were serious and some resulted in death. In an interim safety analysis, the incidence rates (95% CI) for PE for tofacitinib 10 mg twice daily,
tofacitinib 5 mg twice daily, and TNF inhibitors were 0.54 (0.32-0.87), 0.27 (0.12-0.52), and 0.09 (0.02-0.26) patients with events per 100 patient-years, respectively. Compared with TNF inhibitors, the hazard ratio (HR) for PE was 5.96 (1.75-20.33) and 2.99 (0.81-11.06) for tofacitinib 10 mg twice daily and tofacitinib 5 mg twice daily, respectively (see section 5.1).

In a subgroup analysis in patients with VTE risk factors in the above-mentioned interim analysis of the study, the risk for PE was further increased. Compared with TNF inhibitors, the HR for PE was 9.14 (2.11-39.56) for tofacitinib 10 mg twice daily and 3.92 (0.83-18.48) for tofacitinib 5 mg twice daily.

**Myocardial infarction**

*Rheumatoid arthritis*

In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, the incidence rates (95% CI) for non-fatal myocardial infarction for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors were 0.37 (0.22, 0.57), 0.33 (0.19, 0.53), and 0.16 (0.07, 0.31) patients with events per 100 patient-years, respectively. Few fatal myocardial infarctions were reported with rates similar in patients treated with tofacitinib compared to TNF inhibitors (see sections 4.4 and 5.1). The study required at least 1500 patients to be followed for 3 years.

**Malignancies excluding NMSC**

*Rheumatoid arthritis*

In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, the incidence rates (95% CI) for lung cancer for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors were 0.23 (0.12, 0.40), 0.32 (0.18, 0.51), and 0.13 (0.05, 0.26) patients with events per 100 patient-years, respectively (see sections 4.4 and 5.1). The study required at least 1500 patients to be followed for 3 years.

The incidence rates (95% CI) for lymphoma for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors were 0.07 (0.02, 0.18), 0.11 (0.04, 0.24), and 0.02 (0.00, 0.10) patients with events per 100 patient-years, respectively (see sections 4.4 and 5.1).

5.1. Pharmacodynamic properties

**Long-term controlled safety data**

Study ORAL Surveillance (A3921133) is was a large (N=4362), ongoing, randomised active-controlled post-authorisation safety surveillance study of rheumatoid arthritis patients who were at least 50 years of age and older and had at least one additional cardiovascular risk factor (CV risk factors defined as: current cigarette smoker, diagnosis of hypertension, diabetes mellitus, family history of premature coronary heart disease, history of coronary artery disease including a history of revascularization procedure, coronary artery bypass grafting, myocardial infarction, cardiac arrest, unstable angina, acute coronary syndrome, and presence of extra-articular disease associated with RA, e.g. nodules, Sjögren's syndrome, anemia of chronic disease, pulmonary manifestations). Patients were required to be on a stable dose of methotrexate at study entry; dose adjustment was permitted during the study.

Patients were randomised to open-label tofacitinib 10 mg twice daily, tofacitinib 5 mg twice daily, or a TNF inhibitor (TNF inhibitor was either etanercept 50 mg once weekly or adalimumab 40 mg every other week) in a 1:1:1 ratio. The co-primary endpoints were adjudicated malignancies excluding NMSC and adjudicated major adverse cardiovascular events (MACE); cumulative incidence and statistical assessment of endpoints were blinded. The study was an event-powered study that also required at least 1500 patients to be followed for 3 years. The study treatment of tofacitinib 10 mg twice daily has been stopped and patients were switched to 5 mg twice daily because of a dose-dependent signal of venous thromboembolic events (VTE). For patients in the tofacitinib 10 mg twice daily treatment arm, the data collected before and after the dose switch were analysed in their originally randomised treatment group.

The study did not meet the non-inferiority criterion for the primary comparison of the combined tofacitinib doses to TNF inhibitor since the upper limit of the 95% CI for HR exceeded the pre-specified non-inferiority criterion of 1.8 for adjudicated MACE and adjudicated malignancies excluding NMSC.
Final results are provided below for MACE, myocardial infarction, malignancies excluding NMSC, lung cancer and lymphoma for each randomised treatment arm. Interim safety analysis (2019) results are provided for VTE, serious infections, and mortality.

**MACE (including myocardial infarction)**

An increase in non-fatal myocardial infarction was observed in patients treated with tofacitinib compared to TNF inhibitor.

Table 12: Incidence rate and hazard ratio for MACE and myocardial infarction

<table>
<thead>
<tr>
<th></th>
<th>Tofacitinib 5 mg twice daily</th>
<th>Tofacitinib 10 mg twice daily</th>
<th>All Tofacitinib</th>
<th>TNF inhibitor (TNFi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MACE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>0.91 (0.67, 1.21)</td>
<td>1.05 (0.78, 1.38)</td>
<td>0.98 (0.79, 1.19)</td>
<td>0.73 (0.52, 1.01)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>1.24 (0.81, 1.91)</td>
<td>1.43 (0.94, 2.18)</td>
<td>1.33 (0.91, 1.94)</td>
<td></td>
</tr>
<tr>
<td>Fatal MI:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>0.00 (0.00, 0.07)</td>
<td>0.06 (0.01, 0.18)</td>
<td>0.03 (0.01, 0.09)</td>
<td>0.06 (0.01, 0.17)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>0.00 (0.00, Inf)</td>
<td>1.03 (0.21, 5.11)</td>
<td>0.50 (0.10, 2.49)</td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>0.37 (0.22, 0.57)</td>
<td>0.33 (0.19, 0.53)</td>
<td>0.35 (0.24, 0.48)</td>
<td>0.16 (0.07, 0.31)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>2.32 (1.02, 5.30)</td>
<td>2.08 (0.89, 4.86)</td>
<td>2.20 (1.02, 4.75)</td>
<td></td>
</tr>
</tbody>
</table>

- The tofacitinib 10 mg twice daily treatment group includes data from patients that were switched from tofacitinib 10 mg twice daily to tofacitinib 5 mg twice daily as a result of a study modification.
- Combined tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily.
- Based on events occurring on treatment or within 60 days of treatment discontinuation.

Abbreviations: MACE = major adverse cardiovascular events, MI = myocardial infarction, TNF = tumour necrosis factor, IR = incidence rate, HR = hazard ratio, CI = confidence interval, PY = patient years, Inf = infinity.

The following predictive factors for development of MI (fatal and non-fatal) were identified using a multivariate Cox model with backward selection: age ≥ 65 years, male, current or past smoking, history of diabetes, and history of coronary artery disease (which includes myocardial infarction, coronary heart disease, stable angina pectoris, or coronary artery procedures) (see section 4.4 and 4.8).

**Malignancies**

An increase in malignancies excluding NMSC, particularly lung cancer and lymphoma, was observed in patients treated with tofacitinib compared to TNF inhibitor.

Table 13: Incidence rate and hazard ratio for malignancies excluding NMSC

<table>
<thead>
<tr>
<th></th>
<th>Tofacitinib 5 mg twice daily</th>
<th>Tofacitinib 10 mg twice daily</th>
<th>All Tofacitinib</th>
<th>TNF inhibitor (TNFi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>1.13 (0.87, 1.45)</td>
<td>1.13 (0.86, 1.45)</td>
<td>1.13 (0.94, 1.35)</td>
<td>0.77 (0.55, 1.04)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>1.47 (1.00, 2.18)</td>
<td>1.48 (1.00, 2.19)</td>
<td>1.48 (1.04, 2.09)</td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>0.24 (0.12, 0.40)</td>
<td>0.32 (0.18, 0.51)</td>
<td>0.28 (0.19, 0.39)</td>
<td>0.13 (0.05, 0.26)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>1.84 (0.74, 4.62)</td>
<td>2.50 (1.04, 6.02)</td>
<td>2.17 (0.95, 4.93)</td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (95% CI) per 100 PY</td>
<td>0.07 (0.02, 0.18)</td>
<td>0.11 (0.04, 0.24)</td>
<td>0.09 (0.04, 0.17)</td>
<td>0.02 (0.00, 0.10)</td>
</tr>
<tr>
<td>HR (95% CI) vs TNFi</td>
<td>3.99 (0.45, 35.70)</td>
<td>6.24 (0.75, 51.86)</td>
<td>5.09 (0.65, 39.78)</td>
<td></td>
</tr>
</tbody>
</table>
The following predictive factors for development of malignancies excluding NMSC were identified using a Multivariate Cox model with backward selection: age ≥ 65 years and current or past smoking (see section 4.4 and 4.8).

**Serious infections**

In an interim analysis, for non-fatal serious infections, the incidence rates (95% CI) per 100 patient-years were 3.51 (2.93-4.16), 3.35 (2.78-4.01), and 2.79 (2.28-3.39), for tofacitinib 10 mg and 5 mg twice daily and TNF inhibitors, respectively. The risk of serious (fatal and non-fatal) infections was further increased in patients over 65 years of age, as compared to younger patients in study A3921133.
is appropriate for you. Talk to your doctor straight away if you develop signs and symptoms of a heart attack including severe chest pain or tightness (that may spread to arms, jaw, neck, back), shortness of breath, cold sweat, light headedness or sudden dizziness.

Elderly

[...]

Patients aged 65 years and older may be at increased risk of infections, heart attack and some types of cancer. Your doctor may decide that XELJANZ is not suitable for you.

4. Possible side effects

Possible serious side effects

In rare cases, infection may be life-threatening

Lung cancer, white blood cell cancer and heart attack have also been reported.

Signs of blood clots in lungs or veins (uncommon: venous thromboembolism) include

[...]

Signs of a heart attack (uncommon) include

• severe chest pain or tightness (that may spread to arms, jaw, neck, back)
• shortness of breath
• cold sweat
• light headedness or sudden dizziness

Uncommon (may affect up to 1 in 100 people): lung cancer [...]

Rare (may affect up to 1 in 1,000 people): blood infection (sepsis), lymphoma (white blood cell cancer) [...]

1.3. COVID-19 vaccine (ChAdOx1-S [recombinant]) – Vaxzevria – Capillary leak syndrome

<table>
<thead>
<tr>
<th>Authorisation procedure</th>
<th>Centralised</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPITT No</td>
<td>19672</td>
</tr>
<tr>
<td>PRAC rapporteur(s)</td>
<td>Jean-Michel Dogné (BE)</td>
</tr>
<tr>
<td>Date of adoption</td>
<td>10 June 2021</td>
</tr>
</tbody>
</table>

**Recommendation** [see also section 3]

Having considered the available evidence from case reports in EudraVigilance and the responses from the MAH, the PRAC has agreed that there is at least a reasonable possibility that vaccination with Vaxzevria may be associated with very rare cases of capillary leak syndrome (CLS). Healthcare professionals should be aware of this risk and Vaxzevria must not be administered to individuals with a history of CLS.
The MAH for Vaxzevria (AstraZeneca AB) should submit a variation within a week of publication of the PRAC recommendation (i.e. by 29 June 2021), to amend the product information as described below (new text underlined).

**Summary of product characteristics**

4.3. Contraindications

**Individuals who have previously experienced episodes of capillary leak syndrome (see also section 4.4)**

4.4. Special warnings and precautions for use

**Capillary leak syndrome**

*Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with Vaxzevria. A history of CLS was apparent in some of the cases. Fatal outcome has been reported. CLS is a rare disorder characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted. Individuals with a known history of CLS should not be vaccinated with this vaccine. See also section 4.3.*

4.8. Undesirable effects

**Vascular disorders**

Not known: **Capillary leak syndrome**

**Package leaflet**

2. What you need to know before you are given Vaxzevria

The vaccine must not be given:

*If you have a previous diagnosis of capillary leak syndrome (a condition causing fluid leakage from small blood vessels).*

Warnings and precautions

**Capillary leak syndrome**

*Very rare cases of capillary leak syndrome (CLS) have been reported following vaccination with Vaxzevria. Some affected patients had a previous diagnosis of CLS. CLS is a serious, potentially fatal condition causing fluid leakage from small blood vessels (capillaries) resulting in rapid swelling of the arms and legs, sudden weight gain and feeling faint (low blood pressure). Seek immediate medical attention if you develop these symptoms in the days following vaccination.*

4. Possible side effects

Not known

- **Capillary leak syndrome (a condition causing fluid leakage from small blood vessels)**
## 2. Recommendations for submission of supplementary information

<table>
<thead>
<tr>
<th>INN</th>
<th>Signal (EPITT No)</th>
<th>PRAC Rapporteur</th>
<th>Action for MAH</th>
<th>MAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>Acquired haemophilia (19688)</td>
<td>Ulla Wändel Liminga (SE)</td>
<td>Supplementary information requested (submission by 28 July 2021)</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Bupropion</td>
<td>Acute generalised exanthematous pustulosis (AGEP) (19704)</td>
<td>Liana Gross Martirosyan (NL)</td>
<td>Supplementary information requested (submission by 28 July 2021)</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>COVID-19 mRNA(^4) vaccine (nucleoside-modified) – Comirnaty</td>
<td>Myocarditis and pericarditis (19712)</td>
<td>Menno van der Elst (NL)</td>
<td>Supplementary information requested (submission by 21 June 2021)</td>
<td>BioNTech Manufacturing GmbH</td>
</tr>
<tr>
<td>Lenvatinib</td>
<td>Colitis (19691)</td>
<td>Annika Folin (SE)</td>
<td>Supplementary information requested (submission by 25 August 2021)</td>
<td>Eisai GmbH</td>
</tr>
<tr>
<td>Lumacaftor, ivacaftor</td>
<td>Drug reaction with eosinophilia and systemic symptoms (DRESS) (19702)</td>
<td>Rhea Fitzgerald (IE)</td>
<td>Assess in the next PSUR (submission by 28 July 2021)</td>
<td>Vertex Pharmaceuticals (Ireland) Limited</td>
</tr>
</tbody>
</table>

\(^4\) Messenger ribonucleic acid
\(^5\) Messenger ribonucleic acid
## 3. Other recommendations

<table>
<thead>
<tr>
<th>INN</th>
<th>Signal (EPITT No)</th>
<th>PRAC Rapporteur</th>
<th>Action for MAH</th>
<th>MAH</th>
</tr>
</thead>
</table>
| Cannabidiol; calcineurin inhibitors for systemic use (ciclosporin; tacrolimus); mammalian target of rapamycin (mTOR) inhibitors for systemic use (everolimus; sirolimus; temsiroliimus) | Drug interaction with cannabidiol leading to calcineurin inhibitors and mTOR inhibitors serum levels increased and toxicity (19614) | Ronan Grimes (IE) | · Discuss any new relevant data concerning the interaction with cannabidiol which may have emerged since the previous PRAC recommendation (submission by 25 August 2021)  
· Comment on the proposed texts for their respective active substances / products (submission by 25 August 2021) | Innovator MAHs of calcineurin inhibitors (ciclosporin, tacrolimus) and mTOR inhibitors (sirolimus, everolimus and temsiroliimus)² |
| COVID-19 vaccine (ChAdOx1-S [recombinant]) – Vaxzevria | Capillary leak syndrome (19672) | Jean-Michel Dogné (BE) | · See section 1.3  
· Distribute a direct communication for healthcare professionals (DHPC) according to the text and communication plan agreed with the CHMP  
· Provide responses to list of questions (submission by 8 July 2021) | AstraZeneca AB |
| Olanzapine | Cardiomyopathy (19663) | Kimmo Jaakkola (FI) | Routine pharmacovigilance | MAHs of olanzapine containing products |
| Tofacitinib | Major adverse cardiovascular events (MACE) and malignancies excluding non-melanoma skin cancer (NMSC) from a clinical trial (19382) | Liana Gross Martirosyan (NL) | · See section 1.2  
· Distribute a direct communication for healthcare professionals (DHPC) in line with the agreed communication plan | Pfizer Europe MA EEIG |

² While this follow-up signal procedure is ongoing, MAHs of calcineurin inhibitors and mTOR inhibitors are advised to wait before they submit the variation requested in the recommendation from the 26-29 October 2020 PRAC meeting and to monitor for a new recommendation that will be published on the EMA website at the conclusion of the procedure (expected Q4 - 2021).
<table>
<thead>
<tr>
<th>INN</th>
<th>Signal (EPITT No)</th>
<th>PRAC Rapporteur</th>
<th>Action for MAH</th>
<th>MAH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Update the additional risk minimisation measures (Annex II D)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Update the Pharmacovigilance plan in the risk management plan (RMP)</td>
<td></td>
</tr>
</tbody>
</table>